Our case report underscores the feasibility of this approach in non-VSAA patients with milder aplastic anemia, suggesting that ATG-free regimens combined with TPO-RAs may serve as viable alternatives for SAA patients. The gene discussed is TPO; the disease is idiopathic aplastic anemia.